AstraZeneca’s Moventig (naloxegol) has been approved in the European Union for the treatment of opioid-induced constipation.
The European Commission is allowing the drug’s use in adult patients who have failed to respond to conventional treatment with laxatives.
The once-daily pill is a first-in-class, peripherally-acting mu-opioid receptor antagonist offering a new treatment option to millions of people across Europe who suffer from the condition.
The US Food and Drug Administration issued a green light for Moventig back in September for OIC in adults with non-cancer pain.
Moventig was licensed from Nektar Therapeutics in September 2009.
